Brussels (Belgium), 29 March 2010 - 7:00 AM (CET) - regulated information - UCB
announces today Bert De Graeve and Alexandre Van Damme as candidates to be
appointed as new members of UCB's Board of Directors at the next General
Assembly of UCB.

By the next General Assembly on April 29, 2010, the mandate of Prince Lorenz of
Belgium will come to an end. "After three successful terms as Board member,
Prince Lorenz desired not to be nominated again, as agreed when he picked up his
function. The Board of Directors of UCB and the UCB Executive Committee express
their sincere thanks to Prince Lorenz for his key contributions and healthy
challenges," said Karel Boone, Chairman of the Board of Directors of UCB and
Roch Doliveux, CEO of UCB.

Bert De Graeve is Chief Executive Officer of the Bekaert Group. He also is
member of the International Business Leaders' Advisory Council for the Mayor of
Shanghai (IBLAC), President of the Flanders-China Chamber of Commerce, member of
the Advisory Board of the Conference Board China Center for Economics and
Business in Beijing, member of the Board of the Concours Reine Elisabeth and
Senior Member of the Conference Board New York. Alexandre Van Damme is member of
the Board of Directors of Anheuser-Busch InBev and is a Board member of
InBev-Baillet Latour (non profit organisation). He is also a member of the
Insead International Council and the Solvay Business School Consultative
Counsel.

These two candidates as Board members have been selected with a view to further
broadening the skills of the Board. Following the approval by the next General
Assembly of the proposed resolutions on the agenda, the new Board will include
eight Independent Board members namely: Armand De Decker, Bert De Graeve, Peter
Fellner, Jean-Pierre Kinet, Thomas Leysen, Tom McKillop, Gerhard Mayr, and
Norman Ornstein. Other members of the UCB Board of Directors are: Karel Boone,
Chairman, Evelyn du Monceau, Vice Chair, Roch Doliveux, Executive Director,
Arnoud de Pret, Bridget van Rijckevorsel, Alexandre Van Damme and Gaëtan van de
Werve.



For further information
Nancy Nackaerts, External Communications, UCB
T +32.473.864.414  nancy.nackaerts@ucb.com 

Antje Witte, Investor Relations, UCB
T +32.2.559.9414,antje.witte@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com <http://www.ucb.com>) is a biopharmaceutical
company dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous system and
immunology disorders. Employing approximately 9 000 people in over 40 countries,
UCB generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext
Brussels (symbol: UCB).

Forward looking statement
This press release contains forward-looking statements based on current plans,
estimates and beliefs of management. Such statements are subject to risks and
uncertainties that may cause actual results to be materially different from
those that may be implied by such forward-looking statements contained in this
press release. Important factors that could result in such differences include:
changes in general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate fluctuations and
hiring and retention of its employees.


For the pdf-version of this press release, please click on the link below:



[HUG#1398433]





    Press release (PDF): http://hugin.info/133973/R/1398433/354245.pdf